Xylem stock has delivered a 14.5% gain over the past three years. At a last close of US$125.30, the valuation picture now looks closer to fairly priced than clearly cheap, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to only a modest 9.1% gap to the current price. A 14.5% three year return suggests Xylem has rewarded patient holders, but not at a pace that obviously outstrips what its current pricing might already reflect. For long term holders, the key...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.